Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Food and Drug Administration Approval Letter for Alemtuzumab
Saccadic intrusions: review and update.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
Mitochondrial approaches for neuroprotection.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Substance Name: Amiloride
Molecular properties of epithelial, amiloride-blockable Na+ channels.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Genzyme's Lemtrada resubmission accepted for review by FDA
Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Microglia activation is associated with IFN-α induced depressive-like behavior.
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Laquinimod for multiple sclerosis.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Biomarkers for Brain Disorders: Challenges and Opportunities
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.

Pages